SCHEMBL6786375

SCHEMBL6786375

COC(=O)c1ccc(NC(C)C)cc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.57
ALDH1A1 P00352 7/20 0.44
KDM4E B2RXH2 7/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
ALOX12 P18054 1/20 0.44
ATM Q13315 2/20 0.42
HPGD P15428 2/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
PLAU P00749 1/20 0.40
LTB4R Q15722 1/20 0.39
LMNA P02545 1/20 0.39
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6791675 0.90 TERT (0.71) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6784205 0.87 TERT (0.60) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6787458 0.87 TERT (0.58) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6782397 0.86 TERT (0.64) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6787659 0.85 TERT (0.56) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6782347 0.84 TERT (0.55) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6784696 0.84 TERT (0.67) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL6784219 0.84 TERT (0.78) TERTALDH1A1KDM4EHTTALOX12
SCHEMBL6785041 0.83 TERT (0.56) TERTALDH1A1KDM4EMAPTHTT
SCHEMBL7529702 0.83 TERT (0.54) TERTALDH1A1KDM4EALOX12ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
EP-1261321-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF Boehringer Ingelheim Pharma KG (DE) 2002-12-04 EP disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed
WO-2001007020-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885ALDH1A1 102/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.